Celgene Corp. (CELG)

Cash Flow Statement

Low level of difficulty

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company’s balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Celgene Corp., consolidated cash flow statement

US$ in millions

	12 months ended	Dec 31, 2018		Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014
	Net income
	Depreciation
	Amortization
	Impairment charges
	Deferred income taxes
	Change in value of contingent consideration and success payments
	Gain on sale of business
	Net (gain) loss on sales of debt securities available-for-sale and equity investments
	Fair value adjustments on equity investments
	Share-based compensation expense
	Share-based employee benefit plan expense
	Derivative instruments
	Other, net
	Accounts receivable
	Inventory
	Other operating assets
	Accounts payable and other operating liabilities
	Income tax payable
	Payment of contingent consideration
	Deferred revenue
	Change in current assets and liabilities, excluding the effect of acquisitions
	Adjustments to reconcile net income to net cash provided by operating activities
	Net cash provided by operating activities
	Proceeds from sales of debt securities available-for-sale
	Purchases of debt securities available-for-sale
	Capital expenditures
	Proceeds from sales of equity investment securities
	Purchases of equity investment securities
	Payments for acquisition of businesses, net of cash acquired
	Other investing activities
	Net cash used in investing activities
	Payment for treasury shares
	Proceeds from short-term borrowing
	Principal repayments on short-term borrowing
	Proceeds from the issuance of long-term debt
	Repayments of long-term debt
	Net proceeds (payments) from common equity put options
	Payment of contingent consideration
	Net proceeds from share-based compensation arrangements
	Excess tax benefit from share-based compensation arrangements
	Net cash provided by (used in) financing activities
	Effect of currency rate changes on cash and cash equivalents
	Net increase (decrease) in cash and cash equivalents
	Cash and cash equivalents at beginning of period
	Cash and cash equivalents at end of period

Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-07), 10-K (filing date: 2017-02-10), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-20).

Cash flow statement item	Description	The company
Net cash provided by operating activities	Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.	Celgene Corp.’s net cash provided by operating activities increased from 2016 to 2017 but then slightly declined from 2017 to 2018.
Net cash used in investing activities	Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.	Celgene Corp.’s net cash used in investing activities declined from 2016 to 2017 and from 2017 to 2018.
Net cash provided by (used in) financing activities	Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.	Celgene Corp.’s net cash provided by (used in) financing activities increased from 2016 to 2017 and from 2017 to 2018.

	Celgene Corp.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality